Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Key facts

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Principal Investigator

Yaxia Chen, MD, M.D

Study Principal Investigator

Intervention

nab-paclitaxel combined with carboplatin(drug)

Enrollment

538 target

Eligibility

18-75 years · FEMALE

Timeline

2023 – 2027

Study locations (11)

• Sun Yat-Sen University Cancer Hospital, Guangzhou, Guangdong, China
• Qilu Hospital of Shandong University, Ji'nan, Shandong, China
• Yaxia Chen, Hangzhou, Zhejiang, China
• Sir Run Run Hospital, Hangzhou, Zhejiang, China
• The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
• The Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
• Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
• Ningbo women's and children's Hospital, Ningbo, Zhejiang, China
• The No, 1 People's Hospital of Ningbo, Ningbo, Zhejiang, China
• The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
• The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Collaborators

Jiaxing Maternity and Child Health Care Hospital · Zhejiang University · Second Affiliated Hospital, School of Medicine, Zhejiang University · First Affiliated Hospital of Wenzhou Medical University · Second Affiliated Hospital of Wenzhou Medical University · Sun Yat-Sen University Cancer Center · Qilu Hospital of Shandong University · Ningbo No. 1 Hospital · Ningbo Women & Children's Hospital · Sir Run Run Shaw Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary peritoneal carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07480954
  Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
  Beijing Biotech
• RECRUITINGPHASE1, PHASE2NCT07322094
  CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
  TORL Biotherapeutics, LLC
• RECRUITINGPHASE3NCT06915025
  Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
  Imunon
• RECRUITINGPHASE2NCT07023484
  Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
  The University of Hong Kong
• RECRUITINGPHASE2NCT06639074
  Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
  Mayo Clinic
• RECRUITINGPHASE1NCT06469281
  A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
  Regeneron Pharmaceuticals
• RECRUITINGPHASE2NCT06492070
  Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
  Emory University
• RECRUITINGPHASE2NCT06434610
  A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
  Shanghai Jiaolian Drug Research and Development Co., Ltd

See all trials for Primary peritoneal carcinoma →